BridgeBio Pharma Inc.
NASDAQ · BBIO·San Francisco, CA·Large-cap·Approved
Genetic medicine company with acoramidis (Attruby) approved for ATTR-CM, competing in the growing transthyretin cardiomyopathy market. BridgeBio's pipeline spans genetic diseases including achondroplasia (infigratinib) and hypophosphatasia, all grounded in human genetic insights.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| BridgeBio Corporate Presentation February 2026 | Corporate overview | February 24, 2026 | 92 |